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INTRODUCTION
Despite recent improvements in neonatal respiratory man-
agement, bronchopulmonary dysplasia (BPD) continues to
represent a major cause of mortality and morbidity among
premature infants (1). Histopathologic characteristics of
BPD include airway injury, inflammation, and parenchymal
fibrosis (2-4). Although the pathogenesis of BPD is incom-
pletely understood, inflammation is believed to play a cen-
tral role in the lung injury process leading to the develop-
ment of BPD (5). Neutrophils (5-7) and proinflammatory
cytokines (8-10) have been known to exacerbate the inflam-
matory process of chronic lung disease in premature infants.
Therefore, the investigation on the effectiveness of new ther-
apeutic modalities such as anti-inflammatory agents in the
treatment of BPD is of great interest. 
Erythropoietin (EPO), a 30.4-kD glycoprotein that regu-
lates the rate of red blood cell production, has been used for
many years to treat anemia of prematurity (11, 12). In a
recent animal study (13), treatment of hyperoxia-exposed
newborn rat pups with recombinant human EPO (rhEPO)
significantly improved alveolar structure, enhanced vascular-
ity, and lessened fibrosis. These findings suggest that treat-
ment of premature infants with EPO might reduce the risk
of developing BPD. However, a better understanding of the
action mechanism of EPO must be obtained for translation
of this experimental result to clinical trials in BPD patients. 
Although the precise action mechanism of EPO has not
been elucidated yet, one mechanism that may contribute
greatly to the cytoprotection during BPD is anti-inflamma-
tion. Anti-inflammatory effects of EPO such as inhibition
of leukocyte infiltration and decreased production of pro-
inflammatory cytokines have been observed in various in
vivo studies (14-16). In the present study, we tried to deter-
mine whether recombinant human EPO treatment could
attenuate hyperoxia-induced lung injury, and if so, whether
this protective effect is mediated by the down-modulating
the inflammatory responses in neonatal rats.
MATERIALS AND METHODS
Animal model and treatment
The experimental protocols described herein were review-
ed and approved by the Animal Care and Use Committee of
the Samsung Biomedical Research Institute, Seoul, Korea.
This study also followed the institutional and National Insti-
tutes of Health guidelines for laboratory animal care. Timed
pregnant Sprague Dawley rats were housed in individual
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Erythropoietin Attenuates Hyperoxia-Induced Lung Injury by 
Down-modulating Inflammation in Neonatal Rats 
This study was done to determine whether recombinant human erythropoietin
(rhEPO) treatment could attenuate hyperoxia-induced lung injury, and if so, whether
this protective effect is mediated by the down-modulation of inflammation in neona-
tal rats. Newborn Sprague Dawley rat pups were subjected to 14 days of hyperox-
ia (>95% oxygen) within 10 hr after birth. Treatment with rhEPO significantly atten-
uated the mortality and reduced body weight gain caused by hyperoxia. With rhEPO
treatment, given 3 unit/gm intraperitoneally at 4th, 5th, and 6th postnatal day, hyper-
oxia-induced alterations in lung pathology such as decreased radial alveolar count,
increased mean linear intercept, and fibrosis were significantly improved, and the
inflammatory changes such as myeloperoxidase activity and tumor necrosis fac-
tor-alpha expression were also significantly attenuated. In summary, rhEPO treat-
ment significantly attenuated hyperoxia-induced lung injury by down-modulating
the inflammatory responses in neonatal rats.
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cages with free access to water and laboratory chow, and the
rat pups were delivered spontaneously. The experiment began
within 10 hr after birth and continued through postnatal d
14. Ninety rat pups were divided into four groups: normox-
ia control group (NC, n=8); normoxia with EPO treatment
group (NE, n=8); hyperoxia control group (HC, n=37); and
hyperoxia with EPO treatment group (HE, n=37). Through-
out the experiment, rat pups of NC and NE were kept in
the standard cage with nursing mother rat at room air, and
pups of HC and HE were kept in the standard cage with
mother rat within 50 liter Plexiglas chamber in which hyper-
oxia (>95% oxygen concentration) was maintained. Humidi-
ty was maintained at 50%, and environmental temperature
was maintained at 24℃. To avoid oxygen toxicity of nurs-
ing mother rat, mother rats were rotated daily between lit-
ters in normoxia groups and hyperoxia groups. Pups in NE
and HE were injected with 3 unit/gm of rhEPO (Epokine
prefilled: Erythropoietin alpha, CJ Corp., Seoul, Korea) int-
raperitoneally at 4th, 5th, and 6th postnatal day. Pups in NC
and HC received normal saline administered in the same
way. Survival and body weight of rat pups in each group
were checked daily throughout the experiment, and sacri-
ficed at postnatal d 14 after intraperitoneal injection of keta-
mine (Yuhan corp., Seoul, Korea, 50 mg/kg).
Tissue preparation
The lungs were resected after perfusion of the heart with
normal saline. Right lung was saved for later biochemical
analyses. Left lung was fixed in situ at a constant inflation of
20 cmH2O pressure, and then fixed overnight in 10% buffer-
ed formalin. The fixed lung tissue was embedded in paraffin
wax after tissue processing. Five-micrometer thick sections
were cut from the paraffin blocks, and stained with hema-
toxylin and eosin. Images of each section were captured with
a Magnafire digital camera through an Olympus BX40 micro-
scope (Olympus optical co. Ltd., Tokyo, Japan) and were saved
JPEG files. Analysis of each section was carried out in a blind
fashion by a single observer.
Lung histopathology
Alveolarization was assessed by performing radial alveolar
count (RAC), according to the method of Emery and Mithal
(17). From the center of the respiratory bronchiole, a perpen-
dicular line was drawn to the edge of the acinus (as defined
by a connective tissue septum or the pleura), and the num-
ber of septa intersected by this line was counted. 
The inter-alveolar distance was assessed by measuring
mean linear intercept (MLI), obtained by dividing the total
length of lines drawn across the lung section by the number
of intercepts encountered, as described by Cooney and Thurl-
beck (18). 
Each successive lung field was individually assessed for
the severity of interstitial fibrosis and allotted a score 0 and
8 as described by Ashcroft et al. (19) (Fig. 1). A minimum of
10 lung fields per each section were examined for each anal-
ysis. 
Myeloperoxidase
The activity of myeloperoxidase (MPO), an indicator of
neutrophil accumulation, was determined by a modification
of the method by Gray et al. (20). The lung tissues were homo-
genized in a phosphate buffer (pH 7.4) and centrifuged at
30,000 g for 30 min. The pellet was resuspended in another
phosphate buffer (50 mM, pH 6.0) with 0.5% hexadecyl-
trimethyl ammonium bromide. MPO activity in the resus-
pended pellet was assayed by measuring absorbance changes
spectrophotometrically at 460 nm, using 0.167 mg/mL O-
dianisidine hydrochloride and 0.0005% hydrogen peroxide.
One unit of MPO activity was defined as the quantity of
enzyme degrading 1  M of peroxide/min,  
Tumor necrosis factor-alpha (TNF- )
Total RNA was isolated from lung tissues using the Trizol
reagent (Invitrogen, Carlsbad, CA, U.S.A.) according to the
manufacturer’s protocol. First-strand complementary DNA
(cDNA) was synthesized using random primers and the AMV
reverse transcriptase (Promega Corp., Madison, WI, U.S.A.).
RT-generated cDNA encoding TNF-a glyceraldehyde-3-phos-
phate dehydrogenase (GAPDH) was amplified using PCR.
The housekeeping gene GAPDH was used as an internal
standard. The primers used were for rat-specific TNF- and
Fig. 1. Representative photomicrographs showing Grade 1 (A),
Grade 3 (B), Grade 5 (C), and Grade 7 (D) fibrosis, respectively
(H&E, magnification, ×40). 
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GAPDH. PCR reactions were initiated at 94℃ for 3 min,
followed by 35 cycles of amplication (denaturation at 94℃for
1 min, annealing at 55℃ for 1 min, and extension at 72℃
for 1 min) with a final primer extension at 72℃ for 5 min.
The PCR products were separated on 1.5% agarose gel and
stained with ethidium bromide. The intensity of each mRNA
band was quantified by densitometry using a gel documenta-
tion and analysis system and normalized to values for GAPDH.
Statistical analysis
All data were presented as the mean±standard deviation.
Statistical comparison between each group was performed
by one-way analysis of variance with Bonferroni’s correction.
For comparison of survival curves, Kaplan-Meiyer analysis
was performed. A p value of <0.05 was considered signifi-
cant. 
RESULTS
Survival rate and body weight gain
Exposure to oxygen (HC) significantly decreased the sur-
vival rate at the end of experiment (postnatal d 14) compared
to normoxia groups (NC and NE) (27% vs. 88%, p<0.05),
and this hyperoxia-induced decreased survival rate was in-
creased to 41% with EPO treatment (HE) (Fig. 2).
Although birth weight was not different between the four
groups, pups nursed in hyperoxia (HC) showed a significant-
ly reduced body weight gain compared to normoxia groups
(NC, NE) both at postnatal d 7 and 14, and this hyperoxia-
induced decrease in body weight was increased at postnatal
d 14 with EPO treatment (HE) (Table 1). 
Lung histopathology
In morphometric analyses, significantly decreased RAC
and increased MLI were observed in HC compared to nor-
moxia groups (NC and NE) (Fig. 4A, B). These hyperoxia-
induced morphometric abnormalities were significantly im-
S
u
r
v
i
v
a
l
 
r
a
t
e
 
(
%
)
120
100
80
60
40
20
0
13579 1 1 1 3
Postnatal day
HE
HC
NE
NC
Fig. 2. Survival rate in each experimental group. 
NC, Normoxia control group; NE, Normoxia with erythropoietin
treatment group; HC, Hyperoxia control group; HE, Hyperoxia
with erythropoietin treatment group.
*p value <0.05 compared to NC; 
� p value <0.05 compared to
NE; 
� p value <0.05 compared to HC.
Fig. 3. Effect of eythropoietin treatment on lung histology after
hyperoxia in newborn rats. (H&E, magnification, ×40). (A) Lung
structure of neonatal rats in normoxia at d 14 (NC). (B) Erythro-
poietin treatment has no apparent affect on the lung structure of
rats maintained in normoxia (NE). (C) As shown, hypeoxia decreas-
es lung septation and causes lung septation and causes distal
air space enlargement (HC). (D) Erythropoietin treatment during
hyperoxia increases alveolarization (HE).
A B
C D
All values given are mean±standard deviation.
NC, normoxia control group; NE, normoxia with erythropoietin treat-
ment group; HC, hyperoxia control group; HE, hyperoxia with erythro-
poietin treatment group.
*p value <0.05 compared to NC; 
� p value <0.05 compared to NE; 
� p
value <0.05 compared to HC.
NC
(N=8)
NE
(N=8)
HC
(N=37)
HE
(N=37)
Weight (g) 7.1±0.2 7.03±0.18 7.1±0.3 7.0±0.2
on 1st day 
Weight (g) 16.1±1.7 15.5±1.6 12.8±1.0*,� 13.2±1.1*,�
on 7th day 
Weight (g) 31.9±4.1 32.0±3.8 25.1±4.3*,� 28.1±2.5
on 14th day 
Table 1. Body weight gain in each experimental group 
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proved with rhEPO treatment (HE).  
Representative photomicrographs showing histopathologic
differences in each are given in Fig. 3. The significantly in-
creased fibrosis score observed in HC compared to normoxia
goups (NC and NE) was also improved with rhEPO treat-
ment (HE) (Fig. 4C).
MPO and TNF-
The significantly increased MPO activity and TNF- ex-
pression observed in HC compared to normoxia groups (NC
and NE) were significantly improved with rhEPO treatment
(HE) (Fig. 5).
DISCUSSION
The development of an appropriate animal model that can
simulate the clinical BPD of the premature infants is diffi-
cult. In the present study, prolonged exposure of newborn rat
pups to hyperoxia developed lung injuries similar to that seen
in human infants with BPD (2), exhibiting decreased alveo-
larization as evidenced by decreased RAC and increased MLI
(3) and markedly increased fibrosis (4). Furthermore, the sac-
cular stage of the newborn rat pup is compatible to the lung
development of premature infants at 25 weeks of gestation.
Hence the newborn rat pup model is a very convenient model
for studying various aspects of BPD. 
Although the precise mechanisms of the hyperoxia-induc-
ed lung injury are unclear, inflammation is believed to play
a central role in the pathogenesis of BPD (5). The number
of neutrophils was persistently increased both in the inter-
stitium and in the airspaces of the lungs of infants with BPD
(6), and inhibition of neutrophil influx into the hypreoxic
lung enhanced postnatal lung growth (7). MPO is an enzyme
contained in and specific for neutrophil lysosomes (14). There-
fore, our data of increased MPO activity observed in the
hyperoxia-induced lung also support the assumption that
neutrophil influx into the lung would play a pivotal role in
the development of BPD (5-7).
Elevation of TNF- represents one of the first pulmonary
responses to hyperoxia (8), and pretreatment with anti-TNF-
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Fig. 4. Histopathologic analysis in each experimental group. (A) Radial alveolar count (RAC), (B) Mean linear interscept (MLI), (C) Fibro-
sis score. *p value <0.05 compared to normoxia control group (NC); 
� p value <0.05 compared to normoxia with EPO group (NE); 
� p value
<0.05 compared to hyperoxia control group (HC).
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Fig. 5. Myeloperoxidase activity (A) and tumor necrosis factor-a expression (B) in each experimental group. *p value <0.05 compared to
Normoxia control group (NC); 
� p value <0.05 compared to Normoxia with EPO group (NE); 
� p value <0.05 compared to hyperoxia control
group (HC).
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antibody significantly attenuated the hyperoxia-induced
lung injury (9). In the present study, TNF- RNA expres-
sion was significantly increased in hyperoxia-induced lungs.
TNF- can also enhance the neutrophil-dependent increase
in endothelial permeability (10), and stimulate the release
of other pro-inflammatory cytokines and oxygen-free radi-
cals from a variety of cells (8). Taken together, these findings
suggest that hyperoxia-induced inflammatory responses lead-
ing to irreversible lung damage and fibrosis are mainly medi-
ated by neutrophils and pro-inflammatory cytokines.
In the present study, rhEPO treatment significantly im-
proved hyperoxia-induced lung damage such as decreased
alveolarization and increased fibrosis. The protective effects
of EPO observed in this and other (13) animal studies sug-
gest that treatment of premature infants with EPO might
reduce the risk of developing BPD. However, a better under-
standing of the action mechanism of EPO must be obtained
for translation of this experimental result to clinical trials in
BPD patients.
The precise mechanisms by which EPO attenuates hyper-
oxia-induced lung injury are not completely understood. It
has already been shown that inflammation plays a pivotal role
in the development of hyperoxic lung injury (5-10). There-
fore, one possible mechanism that might contribute greatly
to the prevention of BPD by EPO is anti-inflammation (14-
16). Potent anti-inflammatory activity of EPO including
inhibition of leukocyte infiltration and reduced levels of pro-
inflammatory cytokines has been reported in various in vivo
studies such as zymosan-induced nonseptic shock (14), cere-
bral ischemia (15), and experimental autoimmune encepha-
lomyelitis (16). In the present study, the anti-inflammatory
effects of EPO such as attenuation of hyperoxia-induced in-
crease in MPO activity, a marker of neutrophil infiltration,
and reduced TNF- expression have also been observed. Fur-
thermore, as pulmonary inflammation is a key feature in the
pathogenesis of fibrosis in BPD, significant attenuation of
hyperoxia-induced fibrosis with EPO treatment observed in
this and other (13) animal study suggests that anti-inflam-
matory activity of EPO might be responsible for this pro-
tection. 
In summary, rhEPO treatment significantly attenuated
hyperoxia-induced lung pathology such as decreased alve-
olization and increased fibrosis by down-modulating the
inflammatory responses in neonatal rats. These findings sup-
port the potential use of EPO as a therapeutic agent in the
prevention of BPD. Further studies regarding dosage and
safety will be necessary for the translation of the benefits of
EPO treatment observed in this study into clinical trials.
REFERENCES
1. Jobe AH, Ikegami M. Prevention of bronchopulmonary dysplasia.
Curr Opin Pediatr 2001; 13: 124-9.
2. Northway WH Jr, Rosan RC, Porter DY. Pulmonary disease fol-
lowing respirator therapy of hyaline-membrane disease. Broncho-
pulmonary dysplasia. N Engl J Med 1967; 276: 357-68.
3. Kunig AM, Balasubramaniam V, Markham NE, Morgan D, Mont-
gomery G, Grover TR, Abman SH. Recombinant human VEGF
treatment enhances alveolarization after hyperoxic lung injury in
neonatal rats. Am J Physiol Lung Cell Mol Physiol 2005; 289: 529-
35.
4. Ozer EA, Kumral A, Ozer E, Duman N, Yilmaz O, Ozkal S, Ozkan
H. Effect of retinoic acid on oxygen-induced lung injury in the new-
born rat. Pediatr Pulmonol 2005; 39: 35-40.
5. Jobe AH, Ikegami M. Mechanisms initiating lung injury in the pre-
term. Early Hum Dev 1998; 53: 81-94.
6. Merritt TA, Cochrane CG, Holcomb K, Bohl B, Hallman M, Stray-
er D, Edwards DK 3rd, Gluck L. Elastase and alpha 1-proteinase
inhibitor activity in tracheal aspirates during respiratory distress
syndrome. Role of inflammation in the pathogenesis of bronchopul-
monary dysplasia. J Clin Invest 1983; 72: 656-66.
7. Yi M, Jankov RP, Belcastro R, Humes D, Copland I, Shek S, Swee-
zey NB, Post M, Albertine KH, Auten RL, Tanswell AK. Opposing
effects of 60% oxygen and neutrophil influx on alveologenesis in the
neonatal rat. Am J Respir Crit Care 2004; 170: 1188-96.
8. Lindsay L, Oliver SJ, Freeman SL, Josien R, Krauss A, Kaplan G.
Modulation of hyperoxia-induced TNF-alpha expression in the new-
born rat lung by thalidomide and dexamethasone. Inflammation
2000; 24: 347-56.
9. Wherry JC, Pennington JE, Wenzel RP. Tumor necrosis factor and
the therapeutic potential of anti-tumor necrosis factor antibodies.
Crit Care Med 1993; 21(Suppl 10): S436-40.
10. Gibbs LS, Lai L, Malik AB. Tumor necrosis factor enhances the
neutrophil-dependent increase in endothelial permeability. J Cell
Physiol 1990; 145: 496-500.
11. Juul SE. Nonerythropoietic roles of erythropoietin in the fetus and
neonate. Clin Perinatol 2000; 27: 527-41.
12. Ohls RK. The use of erythropoietin in neonates. Clin Perinatol 2000;
27: 681-96.
13. Ozer EA, Kumral A, Ozer E, Yilmaz O, Duman N, Ozkal S, Koroglu
T, Ozkan H. Effects of erythropoietin on hyperoxic lung injury in
neonatal rats. Pediatr Res 2005; 58: 38-41.
14. Cuzzocrea S, Di Paola R, Mazzon E, Patel NS, Genovese T, Muia
C, Crisafulli C, Caputi AP, Thiemermann C. Erythropoietin reduces
the development of nonseptic shock induced by zymosan in mice.
Crit Care Med 2006; 34: 1168-77.
15. Villa P, Bigini P, Mennini T, Agnello D, Laragione T, Cagnotto A,
Viviani B, Marinovich M, Cerami A, Coleman TR, Brines M, Ghezzi
P. Erythropoietin selectively attenuates cytokine production and
inflammation in cerebral ischemia by targeting neuronal apoptosis.
J Exp Med 2003; 198: 971-5.
16. Agnello D, Bigini P, Villa P, Mennini T, Cerami A, Brines ML,
Ghezzi P. Erythropoietin exerts an anti-inflammatory effect on the
CNS in a model of experimental autoimmune encephalomyelitis.
Brain Res 2002; 952: 128-34.
17. Cooney TP, Thurlbeck WM. The radial alveolar count method of
Emery and Mithal: a reappraisal 1--postnatal lung growth. ThoraxErythropoietin for Hyperoxic Neonatal Lung Injury 1047
1982; 37: 572-9.
18. Cooney TP, Thurlbeck WM. The radial alveolar count method of
Emery and Mithal: a reappraisal 2--intrauterine and early postna-
tal lung growth. Thorax 1982; 37: 580-3.
19. Ashcroft T, Simpson JM, Timbrell V. Simple method of estimating
severity of pulmonary fibrosis on a numerical scale. J Clin Pathol
1988; 41: 467-70.
20. Gray KD, Simovic MO, Chapman WC, Blackwell TS, Christman
JW, May AK, Parman KS, Stain SC. Endotoxin potentiates lung
injury in cerulein-induced pancreatitis. Am J Surg 2003; 186: 526-30.